Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hydroxychloroquine + methotrexate + prednisone
- Development stage
- Phase 3
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
A combination therapy regimen consisting of hydroxychloroquine, methotrexate, and prednisone, primarily used to treat autoimmune conditions such as rheumatoid arthritis. This triple therapy works through complementary mechanisms to reduce inflammation, modify disease progression, and provide symptom relief. Methotrexate acts as the primary disease-modifying antirheumatic drug (DMARD), hydroxychloroquine enhances methotrexate's effectiveness through synergistic action, and prednisone provides rapid anti-inflammatory effects while the slower-acting DMARDs take effect.
02
Targets
DNADHFR (Dihydrofolate reductase)GR (Glucocorticoid receptor)GART (GAR transformylase)TS (Thymidylate synthase)TLR7 (Toll-like receptor 7)TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on hydroxychloroquine + methotrexate + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hydroxychloroquine + methotrexate + prednisone.